Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2019 - 2026)

Zentalis Pharmaceuticals' Capital Expenditures history runs 7 years deep, the most recent figure standing at $34000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $34000.0; the TTM figure through Mar 2026 stood at $34000.0 (down 81.22% YoY), while the FY2024 annual figure was $221000.0, down 62.09% from the prior year.
• Capital Expenditures for Q1 2026 stood at $34000.0, down from $181000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $2.3 million in Q3 2022, with the low at -$135000.0 in Q2 2022.
• The 4-year median for Capital Expenditures is $166500.0 (2022), against an average of $338600.0.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures slumped 116.48% in 2022, then surged 336.3% in 2023.
• Zentalis Pharmaceuticals' Capital Expenditures stood at $160000.0 in 2022, then increased by 8.12% to $173000.0 in 2023, then advanced by 4.62% to $181000.0 in 2024, then slumped by 81.22% to $34000.0 in 2026.
• Business Quant data shows ZNTL's Capital Expenditures at $34000.0 in Q1 2026, $181000.0 in Q2 2024, and $40000.0 in Q1 2024.